Literature DB >> 24121312

Correlation of (18)F-fluoromisonidazole PET findings with HIF-1α and p53 expressions in head and neck cancer: comparison with (18)F-FDG PET.

Takashi Norikane1, Yuka Yamamoto, Yukito Maeda, Nobuyuki Kudomi, Toru Matsunaga, Reiji Haba, Akinori Iwasaki, Hiroshi Hoshikawa, Yoshihiro Nishiyama.   

Abstract

OBJECTIVE: We evaluated tumor hypoxia using F-fluoromisonidazole (F-FMISO) PET in relation to the expression of hypoxia-inducible factor-1α (HIF-1α) and p53 in patients with head and neck cancer and compared the results with those obtained using 2-deoxy-2-F-fluoro-D-glucose (F-FDG) PET.
MATERIALS AND METHODS: A total of 28 tumors (23 primary tumors and five metastatic lymph nodes) from 24 patients with newly diagnosed head and neck cancer were examined with F-FMISO PET and F-FDG PET. The F-FMISO PET images were scaled to the venous blood concentration of F-FMISO activity to produce tumor-to-blood (T/B) values. Hypoxia was defined as a region with a T/B ratio greater than or equal to 1.2. The maximum T/B (T/Bmax) and hypoxic volumes were calculated by region-of-interest analysis. For F-FDG PET, the maximum standardized uptake value (SUVmax) and hypermetabolic volume were calculated by region-of-interest analysis. The expressions of HIF-1α and p53 using immunohistochemistry were estimated in tumor tissue samples.
RESULTS: A weak correlation was observed between hypoxic volume and T/Bmax (r=0.53, P=0.003) on using F-FMISO PET and between hypermetabolic volume and SUVmax (r=0.38, P=0.046) on using F-FDG PET. The hypoxic volume using F-FMISO PET and hypermetabolic volume using F-FDG PET also showed a weak correlation (r=0.44, P=0.020). The values of F-FMISO hypoxic volume showed a weak correlation with HIF-1α (r=0.40, P=0.037) and p53 (r=0.47, P=0.012) obtained on immunohistochemical examination.
CONCLUSION: This study demonstrates a weak correlation between hypoxic volume measured by F-FMISO PET and expressions of HIF-1α and p53 in head and neck cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24121312     DOI: 10.1097/MNM.0000000000000010

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  13 in total

Review 1.  Longitudinal PET imaging of tumor hypoxia during the course of radiotherapy.

Authors:  Sonja Stieb; Afroditi Eleftheriou; Geoffrey Warnock; Matthias Guckenberger; Oliver Riesterer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-20       Impact factor: 9.236

Review 2.  Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors:  Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 3.  Imaging for Response Assessment in Cancer Clinical Trials.

Authors:  Anna G Sorace; Asser A Elkassem; Samuel J Galgano; Suzanne E Lapi; Benjamin M Larimer; Savannah C Partridge; C Chad Quarles; Kirsten Reeves; Tiara S Napier; Patrick N Song; Thomas E Yankeelov; Stefanie Woodard; Andrew D Smith
Journal:  Semin Nucl Med       Date:  2020-06-10       Impact factor: 4.446

4.  Associations Between [18F]FDG-PET and Complex Histopathological Parameters Including Tumor Cell Count and Expression of KI 67, EGFR, VEGF, HIF-1α, and p53 in Head and Neck Squamous Cell Carcinoma.

Authors:  Alexey Surov; Hans Jonas Meyer; Anne-Kathrin Höhn; Karsten Winter; Osama Sabri; Sandra Purz
Journal:  Mol Imaging Biol       Date:  2019-04       Impact factor: 3.488

5.  Correlative analyses between tissue-based hypoxia biomarkers and hypoxia PET imaging in head and neck cancer patients during radiochemotherapy-results from a prospective trial.

Authors:  Nils H Nicolay; Nicole Wiedenmann; Michael Mix; Wolfgang A Weber; Martin Werner; Anca L Grosu; Gian Kayser
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-07       Impact factor: 9.236

6.  Hypoxia, blood flow and metabolism in squamous-cell carcinoma of the head and neck: correlations between multiple immunohistochemical parameters and PET.

Authors:  Tove J Grönroos; Kaisa Lehtiö; Karl-Ove Söderström; Pauliina Kronqvist; Jukka Laine; Olli Eskola; Tapio Viljanen; Reidar Grénman; Olof Solin; Heikki Minn
Journal:  BMC Cancer       Date:  2014-11-24       Impact factor: 4.430

7.  Noninvasive evaluation of 18F-FDG/18F-FMISO-based Micro PET in monitoring hepatic metastasis of colorectal cancer.

Authors:  Mingyu Zhang; Huijie Jiang; Rongjun Zhang; Hailong Xu; Hao Jiang; Wenbin Pan; Xin Li; Yiqiao Wang; Song Wang
Journal:  Sci Rep       Date:  2018-12-13       Impact factor: 4.379

8.  [18F]FMISO PET/CT as a preoperative prognostic factor in patients with pancreatic cancer.

Authors:  Tomohiko Yamane; Masayasu Aikawa; Masanori Yasuda; Kenji Fukushima; Akira Seto; Koujun Okamoto; Isamu Koyama; Ichiei Kuji
Journal:  EJNMMI Res       Date:  2019-05-09       Impact factor: 3.138

Review 9.  18F-Fluoromisonidazole in tumor hypoxia imaging.

Authors:  Zuoyu Xu; Xiao-Feng Li; Hongyan Zou; Xilin Sun; Baozhong Shen
Journal:  Oncotarget       Date:  2017-10-07

Review 10.  The Promise of Novel Biomarkers for Head and Neck Cancer from an Imaging Perspective.

Authors:  Loredana G Marcu; Paul Reid; Eva Bezak
Journal:  Int J Mol Sci       Date:  2018-08-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.